Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
116.11
+3.27 (2.89%)
Aug 12, 2026, 1:46 PM EDT - Market open
Rhythm Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 239.92 | 189.76 | 130.13 | 77.43 | 23.64 | 3.15 | |
Revenue Growth | 53.51% | 45.83% | 68.06% | 227.56% | 649.46% | - |
Cost of Revenue | 26.39 | 19.49 | 13.37 | 9.3 | 2.13 | 0.6 |
Gross Profit | 213.53 | 170.27 | 116.76 | 68.13 | 21.51 | 2.56 |
Selling, General & Admin | 240.95 | 194.94 | 144.3 | 117.53 | 92.03 | 68.49 |
Research & Development | 173.21 | 167.34 | 237.96 | 134.95 | 108.63 | 104.13 |
Total Operating Expenses | 414.16 | 362.28 | 382.26 | 252.48 | 200.66 | 172.61 |
Operating Income | -200.63 | -192.02 | -265.5 | -184.36 | -179.16 | -170.06 |
Interest Income | 15.19 | 15.29 | 14.71 | 13.95 | 4.03 | 0.45 |
Interest Expense | -18.48 | -20.58 | -20.6 | -13.89 | -5.2 | - |
Other Non-Operating Income (Expense) | -0.36 | 1.26 | 11.14 | 0.19 | -0.79 | 100 |
Total Non-Operating Income (Expense) | -3.65 | -4.03 | 5.25 | 0.24 | -1.96 | 100.45 |
Pretax Income | -204.28 | -196.04 | -260.26 | -184.11 | -181.12 | -69.61 |
Provision for Income Taxes | 1.07 | 0.5 | 0.35 | 0.56 | - | - |
Net Income | -49.3 | -196.54 | -260.6 | -184.68 | -181.12 | -69.61 |
Net Income Attributable to Preferred Dividends | 4.88 | 5.38 | 3.97 | - | - | - |
Net Income to Common | -210.22 | -201.92 | -264.57 | -184.68 | -181.12 | -69.61 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 67 | 65 | 61 | 58 | 52 | 50 |
Shares Outstanding (Diluted) | 67 | 65 | 61 | 58 | 52 | 50 |
Shares Change | 8.07% | 6.54% | 5.76% | 10.65% | 5.08% | 12.40% |
EPS (Basic) | -3.11 | -3.11 | -4.34 | -3.20 | -3.47 | -1.40 |
EPS (Diluted) | -3.11 | -3.11 | -4.34 | -3.20 | -3.47 | -1.40 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -105.35 | -116.63 | -113.88 | -136.2 | -173.71 | -146.44 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -1.56 | -1.79 | -1.87 | -2.36 | -3.33 | -2.95 |
Gross Margin | 89.00% | 89.73% | 89.73% | 87.99% | 90.98% | 81.01% |
Operating Margin | -83.62% | -101.19% | -204.04% | -238.10% | -757.92% | -5391.85% |
Profit Margin | -20.55% | -103.57% | -200.27% | -238.52% | -766.22% | -2207.10% |
FCF Margin | -43.91% | -61.46% | -87.51% | -175.91% | -734.87% | -4642.90% |
EBITDA | -199.55 | -190.68 | -263.94 | -182.6 | -177.49 | -168.9 |
EBITDA Margin | -83.17% | -100.48% | -202.83% | -235.83% | -750.85% | -5355.14% |
EBIT | -200.63 | -192.02 | -265.5 | -184.36 | -179.16 | -170.06 |
EBIT Margin | -83.62% | -101.19% | -204.04% | -238.10% | -757.92% | -5391.85% |
Effective Tax Rate | -0.52% | -0.25% | -0.13% | -0.31% | 0.00% | 0.00% |